Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: Prospective study in 80 liver transplant recipients

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 8, 2009, Pages 834-842

  Beckebaum, S ^a   Klein, C ^a   Varghese, J ^a   Sotiropoulos, G C ^a   Saner, F ^a   Schmitz, K ^a   Gerken, G ^a   Paul, A ^a   Cicinnati, V R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; REPAGLINIDE; TACROLIMUS;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PARESTHESIA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURIGO; RISK REDUCTION; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 70349227097     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04099.x     Document Type: Article

References (61)

1. Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999 68 : 1195 1198.
2. Gonzalez-Pinto IM, Rimola A, Margarit C, et al. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. Transplant Proc 2005 37 : 1713 1715.
3. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998 66 : 493 499.
4. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007 7 : 137 141.
5. Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001 7 : 533 539.
6. Cantarovich D, Renou M, Megnigbeto A, et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 2005 79 : 72 8.
7. Klein IH, Abrahams A, van ET, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002 73 : 732 736.
8. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004 4 : 937 945.
9. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005 5 : 1111 1119.
10. Ott R, Bussenius-Kammerer M, Reck T, et al. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients. Transpl Int 2004 17 : 39 43.
11. Zadrazil J, Horak P, Zahalkova J, et al. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009 153 : 67 73.
12. Tang SC, Chan KW, Tang CS, et al. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrol Dial Transplant 2006 21 : 3243 3251.
13. Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation 2008 85 : 1261 1269.
14. Citterio F, Pozzetto U, Romagnoli J, et al. Plasma levels of transforming growth factor-beta1 in renal transplant recipients receiving different immunosuppressive regimens. Transplant Proc 2004 36 : 698 699.
15. Matl I, Viklicky O, Voska L, Lodererova A, Vitko S. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients. Transpl Int 2005 18 : 668 671.
16. Mohamed MA, Robertson H, Booth TA, Balupuri S, Kirby JA, Talbot D. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation 2000 69 : 1002 1005.
17. Selzner N, Durand F, Bernuau J, et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. Transplantation 2001 72 : 1061 1065.
18. Manzarbeitia C, Reich DJ, Rothstein KD, Braitman LE, Levin S, Munoz SJ. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 2001 7 : 93 9.
19. Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997 64 : 938 940.
20. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 : 1206 1252.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 31 (Suppl 1 S55 60.
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 1847.
23. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005 67 : 2089 2100.
24. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 : S1 266.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 470.
26. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007 53 : 766 772.
27. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001 7 : 811 815.
28. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008 14 : 1648 1654.
29. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991 83 : 356 362.
30. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002 105 : 310 315.
31. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24 : 987 1003.
32. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002 73 : 901 906.
33. Guckelberger O, Mutzke F, Glanemann M, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006 12 : 394 401.
34. Appleton CP, Hurst RT, Lee KS, Reuss C, Hentz JG. Long-term cardiovascular risk in the orthotopic liver transplant population. Liver Transpl 2006 12 : 352 355.
35. Chanussot F, Botta-Fridlund D, Lechene de la PP, et al. Effects of cyclosporine and corticosteroids on bile secretion in the rat. Transplantation 1992 54 : 226 231.
36. Hulzebos CV, Bijleveld CM, Stellaard F, et al. Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl 2004 10 : 872 880.
37. Chan FK, Zhang Y, Lee SS, Shaffer EA. The effects of liver transplantation and cyclosporine on bile formation and lipid composition: an experimental study in the rat. J Hepatol 1998 28 : 329 336.
38. Roy A, Kneteman N, Lilly L, et al. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. Transplantation 2006 82 : 494 500.
39. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988 85 : 134 138.
40. Hartmann A, Schwietzer G, Stratmann D, Kaltenbach M, Kober G. Effects of nitrendipine and lisinopril on blood pressure and sodium excretion in ciclosporin-associated hypertension after heart transplantation. Cardiology 1993 83 : 141 149.
41. Rego A, Vargas R, Suarez KR, Foegh ML, Ramwell PW. Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: role of extracellular calcium. J Pharmacol Exp Ther 1990 254 : 799 808.
42. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 1994 93 : 2244 2250.
43. Richards NT, Poston L, Hilton PJ. Cyclosporin A inhibits endothelium-dependent, prostanoid-induced relaxation in human subcutaneous resistance vessels. J Hypertens 1990 8 : 159 163. (Pubitemid 20167769)
44. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997 64 : 436 443.
45. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997 63 : 977 983.
46. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999 318 : 1104 1107.
47. van Duijnhoven EM, Christiaans MH, Boots JM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002 13 : 213 220.
48. Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am J Transplant 2008 8 : 1871 1877.
49. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002 73 : 379 386.
50. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008 8 : 667 672.
51. Munoz SJ, Elgenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 2005 11 : S52 6.
52. Liptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006 2 : 398 404. (Pubitemid 44034190)
53. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998 66 : 59 66.
54. Monsour HP Jr., Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995 15 : 123 132.
55. Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA. Fibrogenic effects of cyclosporin A on the tubulointerstitium: role of cytokines and growth factors. Exp Nephrol 1999 7 : 470 478.
56. Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther 1999 289 : 535 542.
57. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000 69 : SS5 10.
58. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997 64 : 1829 1837.
59. Bicknell GR, Williams ST, Shaw JA, Pringle JH, Furness PN, Nicholson ML. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 2000 87 : 1569 1575.
60. Marcard T, Ivens K, Grabensee B, et al. Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II. Transpl Int 2008 21 : 1153 1162.
61. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy - a clinicopathologic study of 96 patients. Transplantation 1992 53 : 1056 1062.